Zacks Initiates Coverage of RYTHM With Underperform Recommendation

Zacks initiated coverage of RYTHM (RYM) with an Underperform rating, flagging a debt-heavy capital structure ($90.6M of debt as of Q3 2025, largely related‑party convertibles), only $35.6M in cash and near‑term maturities (some as soon as November 2025) that create refinancing and dilution risk. For the first nine months of 2025 RYTHM generated $6.6M of revenue, incurred a $19.7M net loss, recorded $21.5M in SG&A and burned $20.5M of cash; outstanding legal claims exceed $24M and one related party accounts for 18% of receivables, offsetting the firm's strategic pivot to branded hemp‑derived THC beverages/edibles (Señorita acquisition, new product launches and retail placements).

Analysis

Market structure: A failed or distressed RYM primarily benefits larger, well-capitalized cannabis/CPG brands and national distributors (e.g., MJ ETF constituents, TLRY, CGC) that can absorb shelf space; related-party noteholders face largest downside if the company defaults. Pricing power for branded hemp beverages is weak near-term — expectation of promotional pricing and trade allowances to maintain retail placement — compressing gross margins by 200–500 bps versus model assumptions. Cross-asset: expect idiosyncratic spike in RYM implied volatility and borrow costs; small-cap convertible spreads widen and could modestly pressure junk/special-situation credit desks, FX/commodities impact is negligible.

Risk assessment: Tail risks include (A) convertibles maturing Nov 2025 triggering a liquidity crisis, (B) adverse legal verdicts >$24M, and (C) a rapid 30–70% dilution if related-party notes convert at low prices. Immediate (days): volatile trading around filings; short-term (weeks–months): debt negotiation outcomes and retail listing renewals; long-term (12–36 months): success depends on achieving >3x revenue growth and reducing SG&A from 325% to <100% of revenue. Hidden dependencies: heavy receivable concentration (18% related party) and retail delist risk; catalysts are a debt extension by Nov 15, 2025, a sub-$5M legal settlement, or an equity raise >$20M.

Trade implications: Primary trade is an idiosyncratic short in RYM (1–2% NAV) sized for borrow availability, paired with a long position in MJ ETF (inverse 1:1 dollar notional) to neutralize sector moves. Options: if liquid, buy 6–9 month put spreads to cap premium (long 9m ATM put / short deeper OTM put) sized 0.5–1% NAV; if illiquid, use synthetic via short stock + long calls to hedge. Rotate capital away from small-cap cannabis CPGs into larger beverage/CPG winners (PEP, MNST) and maintain higher cash into Oct–Nov 2025.

Contrarian angles: The market may be over-penalizing RYM’s brand pivot — a successful recap (debt-for-equity) executed before Nov 15, 2025 could produce a >2x rally, but probability is low (<20%). Historical parallels: small cannabis brand recapitalizations post-2020 produced sharp rebounds but only after creditor-friendly restructures that diluted legacy shareholders heavily. Unintended consequence: aggressive short pressure could accelerate a negotiated extension or equity rescue that triggers a short squeeze; size positions accordingly and use hard stop-loss at +50% against initial short.

Key Decisions for Investors

• Establish a tactical short position in RYM equal to 1–2% of NAV via borrow or synthetic short immediately; trim/close if company announces debt maturity extension beyond Nov 15, 2025 or an equity raise >$20M that increases shares outstanding by >20%.
• Purchase 6–9 month RYM put spreads (long nearer-term ATM put, short deeper OTM put) sized 0.5–1% NAV to limit premium while capturing downside into the Nov 2025 maturity window; if options are illiquid, replace with a short-stock + long-call hedge of equivalent delta.
• Implement a pair trade: short RYM (dollar) / long MJ ETF (symbol MJ) equal-dollar notional to isolate idiosyncratic execution and refinancing risk; rebalance monthly and unwind the short if RYM liquidity position improves (cash >$60M or operating cash flow turns positive for three consecutive months).
• Reduce broader small-cap cannabis/CPG exposure by 1–3% of portfolio and redeploy into larger beverage/CPG names (e.g., PEP, MNST) or cash ahead of critical catalysts (Oct–Nov 2025); set hard stop-loss on RYM short at +50% adverse move and cover on confirmed debt-for-equity recap or legal settlement < $5M.